9. Social efficiency of introduction of atherosclerosis screening program in Kazakhstan. Systematic review

Авторлар

DOI:

https://doi.org/10.35805/BSK2025I009

Жүктеулер

Аңдатпа

Background. Atherosclerosis, a major cause of cardiovascular disease, has a significant impact on morbidity and mortality in Kazakhstan. The increasing burden of this disease, combined with a high prevalence of dyslipidemia, underscores the importance of effective screening to reduce associated health risks. The aim of this study is to evaluate the social efficiency of implementing a nationwide atherosclerosis screening program in Kazakhstan and to assess its potential to improve public health outcomes and reduce mortality from cardiovascular disease.

Methods. A literature review was conducted, and global screening approaches and protocols for atherosclerosis and cardiovascular disease were analyzed for their applicability in the local context.

Results. Results suggest that targeted and cascade screening programs, particularly those focused on high-risk individuals and familial hypercholesterolemia, are effective in reducing disease incidence and mortality. Implementation of similar protocols in Kazakhstan could improve early detection, allowing for preventive interventions and treatment. The study concludes that a structured, government-sponsored screening program would not only save lives but also provide substantial economic benefits by reducing long-term health care costs associated with cardiovascular complications.

Conclusion. Screening is the convenient and economically efficient way to prevent atherosclerosis, and its effectiveness is demonstrated by worldwide practice and the history of early disease prevention. However, the effectiveness and social value of screening need to be demonstrated before it can be incorporated into medical practice. If established as a regular practice, widespread population screening could dramatically reduce cardiovascular disease, the leading cause of death worldwide.

Кілт сөздер

atherosclerosis, dyslipidemia, cardiovascular diseases, lipid profile, screening

Әдебиеттер тізімі

  1. Sagan A, McDaid D, Rajan S, Far-rington J, McKee M. Screening: When is it appropriate and how can we get it right?
  2. Weber W, Heins A, Jardine L, Stan-ford K, Duber H. Principles of Screening for Disease and Health Risk Factors in the Emergency De-partment. Ann Emerg Med. May 2023;81(5):584-591. doi:10.1016/j.annemergmed.2022.06.015
  3. Bekbossynova MS, Ivanova-Razu-mova TV, Dzhetybayeva SK, Oral-bekova ZO. Cardiology Service of Kazakhstan Today: Acute Coronary Syndrome, Chronic Heart Failure, Atherosclerosis. Kardiologiia. Jan 31 2024;64(1):34-36. doi:10.18087/car-dio.2024.1.n2580
  4. Shamsutdinova A, Turdaliyeva B, Tanabayeva S, et al. Screening for Breast, Cervical and Prostate Cancers in Kazakhstan: Key Fac-tors and Psychological Aspects. Asian Pac J Cancer Prev. Jul 1 2023;24(7):2515-2522. doi:10.31557/APJCP.2023.24.7.2515
  5. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardio-
  6. India State-Level Disease Burden Initiative CVDC. The changing pat-terns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Dis-ease Study 1990-2016. Lancet Glob Health. Dec 2018;6(12):e1339-e1351. doi:10.1016/S2214-109X(18)30407-8
  7. Brant LCC, Nascimento BR, Veloso GA, et al. Burden of Cardiovascular diseases attributable to risk fac-tors in Brazil: data from the "Global Burden of Disease 2019" study. Rev Soc Bras Med Trop. 2022;55(suppl 1):e0263. doi:10.1590/0037-8682-0263-2021
  8. Kochanek KD, Murphy SL, Xu J, Arias E. Deaths: Final Data for
  9. Chen H, Liu L, Wang Y, et al. Bur-den of cardiovascular disease at-tributable to metabolic risks in 204 countries and territories from 1990 to
  10. Lv J, Yang C, Yang X. The global burden of cardiovascular disease attributable to diet high in sug-ar-sweetened beverages among people aged 60 years and older: an analysis for the global burden of dis-ease study
  11. Bekbossynova M, Ivanova-Razu-mova T, Ablayeva A, Oralbeko-va Z. Establishment of an Ath-erosclerosis and Dyslipidemia Program in Kazakhstan. Mayo Clin Proc. Nov 2024;99(11):1698-1701. doi:10.1016/j.mayocp.2024.05.023
  12. Kulak MJ, Los Angeles WL, Dan-iels TE, et al. Increased Cardiomet-abolic Risk in Healthy Young Adults With Early Life Stress. Psychosom Med. Feb-Mar 01 2024;86(2):72-82. doi:10.1097/PSY.0000000000001273
  13. Mehta A, Shapiro MD. Apolipopro-teins in vascular biology and athero-sclerotic disease. Nat Rev Cardiol. Mar 2022;19(3):168-179. doi:10.1038/s41569-021-00613-5
  14. Mehta N, Myrskyla M. The Popula-tion Health Benefits Of A Healthy Lifestyle: Life Expectancy In-creased And Onset Of Disability De-layed. Health Aff (Millwood). Jul 19 2017; doi:10.1377/hlthaff.2016.1569
  15. Timmis A, Townsend N, Gale C, et al. European Society of Cardiology: Car-diovascular Disease Statistics
  16. Liu M, Yao C, Liu S, et al. Intelligent response micelles with high andro-grapholide loading for the effective treatment of atherosclerosis. Int J Pharm. Nov 15 2024;665:124705. doi:10.1016/j.ijpharm.2024.124705
  17. Kronenberg F, Mora S, Stroes ESG, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Athero-sclerosis Society. Atherosclerosis. Jun 2023;374:107-120. doi:10.1016/j.atherosclerosis.2023.04.012
  18. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Ath-erosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treat-ments and clinical guidance. Eur Heart J. Jul 1 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197
  19. Fan J, Kitajima S, Watanabe T, et al. Rabbit models for the study of hu-man atherosclerosis: from patho-physiological mechanisms to trans-lational medicine. Pharmacol Ther. Feb 2015;146:104-19. doi:10.1016/j.pharmthera.2014.09.009
  20. Fernandez-Garcia P, Malet-Engra G, Torres M, et al. Evolving Diagnostic and Treatment Strategies for Pediat-ric CNS Tumors: The Impact of Lip-id Metabolism. Biomedicines. May 5 2023;11(5) doi:10.3390/biomedi-cines11051365
  21. Supiyev A, Nurgozhin T, Zhumadilov Z, Peasey A, Hubacek JA, Bobak M. Prevalence, awareness, treatment and control of dyslipidemia in older persons in urban and rural popula-tion in the Astana region, Kazakh-stan. BMC Public Health. Aug 11 2017;17(1):651. doi:10.1186/s12889-017-4629-5
  22. Boytsov SA, Pogosova NV, Oganov RG, et al. [Efficacy of primary pre-vention for atherosclerosis-induced diseases in patients with high car-diovascular risk in Russia and other European countries (Part 1)]. Kardi-ologiia. SJan 2017;57(S1):333-344. doi:10.18087/cardio.2411
  23. Ignatyeva VI, Voznyuk IA, Shamalov NA, Reznik AV, Vinitskiy AA, Derk-ach EV. [Social and economic bur-den of stroke in Russian Federa-tion]. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(8. Vyp. 2):5-15. Sotsial'no-ekonomicheskoe bre-mya insul'ta v Rossiiskoi Federatsii. doi:10.17116/jnevro20231230825
  24. Pan X, Liu J, Zhong L, et al. Identi-fication of lipid metabolism-related biomarkers for diagnosis and molec-ular classification of atherosclerosis. Lipids Health Dis. Jul 6 2023;22(1):96. doi:10.1186/s12944-023-01864-6
  25. Busnelli M, Manzini S, Colombo A, et al. Lack of ApoA-I in ApoE-KO Mice Causes Skin Xanthomas, Worsening of Inflammation, and In-creased Coronary Atherosclerosis in the Absence of Hyperlipidemia. Arterioscler Thromb Vasc Biol. Jul 2022;42(7):839-856. doi:10.1161/AT-VBAHA.122.317790
  26. Michos ED, McEvoy JW, Blumen-thal RS. Lipid Management for the Prevention of Atherosclerotic Car-diovascular Disease. N Engl J Med. Oct 17 2019;381(16):1557-1567. doi:10.1056/NEJMra1806939
  27. Moiynbayeva S, Akhmetov V, Narym-bayeva N, et al. Health policy impli-cations for cardiovascular disease, type 2 diabetes mellitus, and stroke in Central Asia: a decadal forecast of their impact on women of repro-ductive age. Front Public Health. 2024;12:1456187. doi:10.3389/fpubh.2024.1456187
  28. Duarte Lau F, Giugliano RP. Lipopro-tein(a) and its Significance in Cardio-vascular Disease: A Review. JAMA Cardiol. Jul 1 2022;7(7):760-769. doi:10.1001/jamacardio.2022.0987
  29. Parini P, Frikke-Schmidt R, Tselepis AD, et al. Taking action: European Atherosclerosis Society targets the United Nations Sustainable Devel-opment Goals 2030 agenda to fight atherosclerotic cardiovascular dis-ease in Europe. Atherosclerosis. Apr 2021;322:77-81. doi:10.1016/j.ath-erosclerosis.2021.02.00731.vonEckardsteinA.ImplicationsofEurope'sPlanSforAtherosclerosis.Atherosclerosis.Jan2019;280:202-203.doi:10.1016/j.atherosclero-sis.2018.12.007
  30. Sanin V, Schmieder R, Ates S, et al. Population-based screening in chil-dren for early diagnosis and treat-ment of familial hypercholesterol-emia: design of the VRONI study. Med Genet. Apr 2022;34(1):41-51. doi:10.1515/medgen-2022-2115
  31. Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: The Slovenian model and litera-ture review. Atherosclerosis. Oct 2018;277:383-391. doi:10.1016/j.ath-erosclerosis.2018.06.858
  32. Souto AC, Miname MH, Fukushima J, et al. Health related quality of life in individuals at high risk for famil-ial hypercholesterolemia undergoing genetic cascade screening in Brazil. Atherosclerosis. Oct 2018;277:464-469. doi:10.1016/j.atherosclero-sis.2018.05.036
  33. Bauman CD, Bauman JM, Mourao DM, et al. Dyslipidemia prevalence in adolescents in public schools. Rev Bras Enferm. 2020;73(3):e20180523. doi:10.1590/0034-7167-2018-0523
  34. Lakunchykova O, Averina M, Wils-gaard T, et al. Why does Russia have such high cardiovascular mortality rates? Comparisons of blood-based biomarkers with Norway implicate non-ischaemic cardiac damage. J Epidemiol Community Health. Sep 2020;74(9):698-704. doi:10.1136/jech-2020-213885
  35. Polyakov DS, Fomin IV, Belenkov YN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. Mar 23 2021;61(4):4-14. doi:10.18087/cardio.2021.4.n1628
  36. Chugunova A, Loseva E, Mazin P, et al. LINC00116 codes for a mitochon-drial peptide linking respiration and lipid metabolism. Proc Natl Acad Sci U S A. Mar 12 2019;116(11):4940-4945. doi:10.1073/pnas.1809105116
  37. Deniz MF, Guven B, Ebeoglu AO, et al. Screening for Subclinical Ath-erosclerosis in Patients with Famil-ial Hypercholesterolemia: Insights and Implications. J Clin Med. Jan 20 2025;14(2) doi:10.3390/jcm14020656
  38. Reamy BV. Familial Hypercholester-olemia: Screening, Diagnosis, and Treatment. Am Fam Physician. Sep 2024;110(3):226
  39. Wald DS, Wald NJ. Integra-tion of child-parent screening and cascade testing for famil-ial hypercholesterolaemia. J Med Screen. Jun 2019;26(2):71-75. doi:10.1177/0969141318796856
  40. Bulanova N, Ivanov G. [Ecg Disper-sion Mapping: Ability to Predict the Patients' Prognosis (Review)]. Geor-gian Med News. Feb 2019;(287):73-78
  41. Shaw LJ, Chandrashekhar Y. Unfold-ing the Importance of Subclinical Atherosclerosis: Is it Time to Start Population Screening? JACC Cardio-vasc Imaging. Sep 2022;15(9):1680-1681. doi:10.1016/j.jcmg.2022.08.001
  42. Abbott AL. Are We Ready for Rou-tine 'Subclinical' Atherosclerosis Screening? Not Yet. Eur J Vasc En-dovasc Surg. Sep 2016;52(3):313-6. doi:10.1016/j.ejvs.2016.06.002
  43. Hung CL, Goncalves A, Shah AM, Cheng S, Kitzman D, Solomon SD. Age- and Sex-Related Influences on Left Ventricular Mechanics in Elderly Individuals Free of Preva-lent Heart Failure: The ARIC Study (Atherosclerosis Risk in Communi-ties). Circ Cardiovasc Imaging. Jan 2017;10(1) doi:10.1161/CIRCIMAG-ING.116.004510
  44. Barzilay JI, Buzkova P, Cauley JA, Robbins JA, Fink HA, Mukamal KJ. The associations of subclinical ath-erosclerotic cardiovascular disease with hip fracture risk and bone min-eral density in elderly adults. Osteo-poros Int. Oct 2018;29(10):2219-2230. doi:10.1007/s00198-018-4611-9
  45. Raitakari O, Pahkala K, Magnussen CG. Prevention of atherosclerosis from childhood. Nat Rev Cardiol. Aug 2022;19(8):543-554. doi:10.1038/s41569-021-00647-9
  46. Witczak-Sawczuk K, Ostrowska L, Cwalina U, Leszczynska J, Jastr-zebska-Mierzynska M, Hladunski MK. Estimation of the Impact of Ab-dominal Adipose Tissue (Subcutane-ous and Visceral) on the Occurrence of Carbohydrate and Lipid Metabo-lism Disorders in Patients with Obe-sity-A Pilot Study. Nutrients. Apr 26 2024;16(9) doi:10.3390/nu16091301
  47. Tran AH, Urbina EM. Is There a Role for Imaging Youth at Risk of Athero-sclerosis? Curr Atheroscler Rep. Apr 2023;25(4):119-126. doi:10.1007/s11883-023-01089-z
  48. Lozano P, Henrikson NB, Morrison CC, et al. Lipid Screening in Child-hood and Adolescence for Detection of Multifactorial Dyslipidemia: Evi-dence Report and Systematic Review for the US Preventive Services Task Force. JAMA. Aug 9 2016;316(6):634-44. doi:10.1001/jama.2016.6423
  49. Becker M, Adamski A, Fandel F, et al. Screening for familial hypercho-lesterolaemia in primary school children: protocol for a cross-sec-tional, feasibility study in Luxem-bourg city (EARLIE). BMJ Open. Dec 9 2022;12(12):e066067. doi:10.1136/bmjopen-2022-066067

Жарияланды

2025-03-31

Журналдың саны

№ 1 (2025)

Бөлім

Статьи